Pipeline & Platform
Pearl Therapeutics is developing fixed-dose combination product candidates for the treatment of prevalent chronic respiratory diseases, including chronic obstructive pulmonary disease (COPD), asthma and rhinosinusitis. The Company’s lead product candidates are PT003, a twice-daily, fixed-dose combination of glycopyrronium, a long-acting muscarinic antagonist (LAMA) and formoterol fumarate, a long acting β2-agonist (LABA); and PT001 and PT005, its monotherapy components. These three product candidates are all undergoing Phase 3 clinical testing for the treatment of patients with moderate-to-very severe COPD.
Each of these product candidates incorporates approved drug actives, off-the-shelf metered dose inhaler (MDI) components, conventional manufacturing processes, and Pearl’s innovative proprietary particle platform. Pearl’s products are not approved by the Food and Drug Administration and are not available for commercial distribution in the United States. To learn more about our platform technology, please click here.
Glycopyrronium and formoterol (GFF MDI)
Glycopyrronium (GP MDI)
Formoterol (FF MDI)
Budesonide, glycopyrronium and formoterol (BGF MDI)
Budesonide (BUD MDI)
Budesonide and formoterol (BFF MDI)